Carmela Morace

Prof. Dr. Carmela Morace


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2005 in World Journal of Gastroenterology
Verified
Journal Article
Open access
ASAldo Spadaro
Aldo Spadaro
AAAntonino Ajello
Antonino Ajello
CMCarmela Morace
Carmela Morace
AZAgata Zirilli
Agata Zirilli
GDGraziella D'Arrigo
Graziella D'Arrigo
MFMaria-Antonietta Freni
Maria-Antonietta Freni
Serum chromogranin-A in hepatocellular carcinoma: Diagnostic utility and limits

27 January 2011 in Scandinavian Journal of Gastroenterology
Verified
Journal Article
Closed access
CLCarmelo Luigiano
Carmelo Luigiano
FFFrancesco Ferrara
Francesco Ferrara
CFCarlo Fabbri
Carlo Fabbri
SGStefania Ghersi
Stefania Ghersi
MBMarco Bassi
Marco Bassi
NDNicola D'Imperio
Nicola D'Imperio
The aim of this study was to evaluate the outcomes of through-the-scope (TTS) large diameter self-expanding metal stent (SEMS) placement for palliation of malignant colorectal obstruction. Between January 2005 and December 2009, all patients who underwent endoscopic SEMS placement for palliation of malignant colorectal obstruction were prospectively enrolled. Thirty-nine patients (17M and 22F; mean age 75.9 ± 10.6 years, range 50-91) were enrolled. The most frequent location was the sigmoid colon (13 cases). The causes of obstruction were colorectal malignancy in 32 patients and extracolonic malignancy in 7. Technical success was achieved in 36/39 patients (92.3%) and clinical success in 35/39 patients (89.7%). Technical failure was related to female sex (p = 0.04) and the extracolonic etiology of the stricture (p < 0.001). There were three early complications: two procedure-related perforations successfully managed conservatively and one hemorrhage treated with APC. Early complications were related to the location of strictures at the recto-sigmoid junction (p < 0.001). Late complications occurred in 10 patients: 8 of these patients experienced occlusive symptoms (attributable to tumor ingrowth in 5 cases and stool impaction in 3 cases); the remaining 2 were one case of tumor ingrowth with sub-occlusive symptoms and hemorrhage, and one case of distal migration. There was no procedure-related mortality and all complications were managed without surgical intervention. SEMS patency duration was 236 ± 128 days (range 31-497) and mean survival of the patients was 259 ± 121 days (range, 32-511). In our experience, TTS large-diameter SEMS placement is a safe and effective treatment for palliation of malignant colorectal obstruction.

5 October 2012 in Advances in Therapy
Verified
Journal Article
Closed access
PDF file
CLCarmelo Luigiano
Carmelo Luigiano
FFFrancesco Ferrara
Francesco Ferrara
CMCarmela Morace
Carmela Morace
BMBenedetto Mangiavillano
Benedetto Mangiavillano
CFCarlo Fabbri
Carlo Fabbri
PCPierluigi Consolo
Pierluigi Consolo

1 January 2008 in World Journal of Gastroenterology
Verified
Journal Article
Open access
ASAldo Spadaro
Aldo Spadaro
VTVincenza Tortorella
Vincenza Tortorella
CMCarmela Morace
Carmela Morace
AFAgostino Fortiguerra
Agostino Fortiguerra
PCPaola Composto
Paola Composto
MFMaria Antonietta Freni
Maria Antonietta Freni
High circulating D-dimers are associated with ascites and hepatocellular carcinoma in liver cirrhosis

9 April 2022 in Biomolecules
Verified
Journal Article
Open access
PDF file
ATArianna Toscano
Arianna Toscano
MCMaria Cinquegrani
Maria Cinquegrani
Michele ScuruchiMichele Scuruchi
Michele Scuruchi
Antonino Di PinoAntonino Di Pino
Antonino Di Pino
Salvatore PiroSalvatore Piro
Salvatore Piro
GMGiuseppe Mandraffino
Giuseppe Mandraffino
Proprotein convertase subtilisin/kexin type-9 (PCSK9) is a key regulator of low-density lipoprotein (LDL) metabolism involved in the degradation of the low-density lipoprotein receptor (LDLR) through complex mechanisms. The PCSK9 plasma levels change according to lipid lowering therapy (LLT). Few data exist regarding the role of PCSK9 in vascular damage. We aimed to evaluate the impact of PCSK9 plasma levels on pulse wave velocity (PWV) and the effect of PCSK9 inhibitors (PCSK9-i) on circulating PCSK9 and PWV in a cohort of heterozygous familial hypercholesterolemia (HeFH) subjects. In a previous step, HeFH patients were enrolled and LLT was prescribed according to guidelines. Biochemical analyses and PWV assessment were performed at baseline (T0), after 6 months of high-efficacy statin plus ezetimibe (T1) and after 6 months of PCSK9-i (T2). The PCSK9 levels were evaluated in 26 selected HeFH subjects at the three time points and 26 healthy subjects served as controls for the reference value for PCSK9 plasma levels. The PWV values decreased at each time point in HeFH subjects after LLT starting (8.61 ± 2.4 m/s, −8.7%; p < 0.001 vs. baseline at T1, and 7.9 ± 2.1 m/s, −9.3%; p < 0.001 vs. both T1 and baseline) and it was correlated to PCSK9 (r = 0.411, p = 0.03). The PCSK9 levels increased on statin/EZE therapy (+42.8% at T1) while it decreased after PCSK9-i was started (−34.4% at T2). We noted a significant relationship between PCSK9 levels and PWV changes at T1 and T2. In conclusion, PCSK9 levels were associated with baseline PWV values in HeFH subjects; moreover, we found that PCSK9 level variations seemed to be correlated with PWV changes on LLT. A longer observation time and wider sample size are needed to assess the potential role of PCSK9 plasma levels on the vascular function and remodelling, and to clarify the effects of PCSK9-i in these pathways.

11 May 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
Alberto Lo GulloAlberto Lo Gullo
Alberto Lo Gullo
GMGiuseppe Mandraffino
Giuseppe Mandraffino
JRJavier Rodríguez-Carrio
Javier Rodríguez-Carrio
Michele ScuruchiMichele Scuruchi
Michele Scuruchi
DSDavide Sinicropi
Davide Sinicropi
Giovanni SquadritoGiovanni Squadrito
Giovanni Squadrito
Background: Systemic sclerosis (SSc) is characterized by early vasculopathy and fibrosis in the skin, lungs, and other tissues. Vascular manifestations of SSc include Raynaud’s phenomenon, digital ulcers, and pulmonary artery hypertension (PAH). PAH is the second most common cause of mortality in SSc. Circulating CD34+ cells associated with cardiovascular health status in several conditions, including chronic immune-inflammatory disease. CD34+ cell numbers have been found inconstantly reduced in SSc. Endocan, a proteoglycan expressed by endothelial cells, was recently suggested as a marker of vascular stress. We tested the relationships among CD34+ cells, endocan, inflammatory markers, vitamin D levels, and clinical parameters in SSc patients with PAH. METHODS: Standard echocardiography was performed. Vitamin D levels, CD34+ cells, inflammatory markers, endocan plasma levels were determined in 36 female SSc patients (24 diffuse/12 limited) and 36 matched controls (HC). RESULTS: We found no difference in CD34+ and vitamin D levels in SSc as compared to controls; ESR, CRP, fibrinogen, endocan, sPAP were higher in SSc with respect to controls. We found a correlation between endocan and: CD34+ cells (r: −0.540, p = 0.002), pulmonary arterial pressure (sPAP) (r: 0.565, p < 0.001), tricuspid annular plane excursion (TAPSE) (r: −0.311, p < 0.01), and E/A ratio (r: −0.487, p < 0.001), but not with ejection fraction (r: −0.057, p = 0.785) in SSc. CD34+ cells correlate with fibrinogen (r: −0.619, p < 0.001), sPAP (r: −0.404, p = 0.011), E/A (r: 0.470, p < 0.005 in SSc. CONCLUSION: CD34+ cell number was significantly correlated with endocan levels and with sPAP in SSc; endocan and CD34+ progenitor cells might be suggested as a potential marker of disease status.